Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
about
Endocrine neoplasms in familial syndromes of hyperparathyroidismMIP-Based Sensors: Promising New Tools for Cancer Biomarker Determination.Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an updateThyroid nodule update on diagnosis and management.RETRACTED ARTICLE: Thyroid nodules update in diagnosis and managementRevised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatmentSurgical approach to medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2.Narrowing the gap of personalized medicine in emerging countries: the case of multiple endocrine neoplasias in Brazil.Medullary thyroid carcinoma: The third most common thyroid cancer reviewedPostoperative Complications After Prophylactic Thyroidectomy for Very Young Patients With Multiple Endocrine Neoplasia Type 2: Retrospective Cohort Analysis.Measurement of calcitonin and calcitonin gene-related peptide mRNA refines the management of patients with medullary thyroid cancer and may replace calcitonin-stimulation tests.A differential diagnosis of inherited endocrine tumors and their tumor counterpartsThe evolution of biomarkers in thyroid cancer-from mass screening to a personalized biosignature.Multiple endocrine neoplasia similar to human subtype 2A in a dog: Medullary thyroid carcinoma, bilateral pheochromocytoma and parathyroid adenoma.Unusual Cushing's Syndrome and Hypercalcitoninaemia due to a Small Cell Prostate Carcinoma.Routine calcitonin measurement in nodular thyroid disease management: is it worthwhile?RET haplotype, not linked to the C620R activating mutation, associated with Hirschsprung disease in a novel MEN2 family.Medullary thyroid cancer diagnosis: an appraisal.Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES).Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association.Metastatic neuroendocrine tumor of the esophagus with features of medullary thyroid carcinoma.Calcitonin-Secreting Neuroendocrine Carcinoma of Larynx with Metastasis to Thyroid.Hypercalcitoninemia and thyroid nodules: when cytology (still) matters.A cut-off value of basal serum calcitonin for detecting macroscopic medullary thyroid carcinoma.Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test?Hypercalcitoninemia in thyroid conditions other than medullary thyroid carcinoma: a comparative analysis of calcium and pentagastrin stimulation of serum calcitonin.Patients with papillary thyroid carcinoma associated with high stimulated serum calcitonin levels.Calcium-stimulated calcitonin - The "new standard" in the diagnosis of thyroid C-cell disease - clinically relevant gender-specific cut-off levels for an "old test"
P2860
Q26747174-02F7378E-405F-4402-BA8C-F82DD064122BQ30356800-2412DC35-A11C-49C5-83A9-9E4CD252031CQ33587821-34CF0E73-78C9-4AC6-8BF3-FEED6BC21AC0Q33801964-38D68080-5F65-4E4F-B03E-31FA3163DD5BQ33802433-22F50A28-CFB2-4314-B07D-71BAB7135D91Q34468665-431FE623-E744-4CC4-908B-5C96A687D86BQ34894198-FB00EADF-37B6-48E0-BFFB-613AA58957E5Q35895469-23C9B6D9-C8F6-4226-9945-01F2EBDF9B0BQ35895509-CBBF5FFA-6959-48AB-B451-11CDC5C87B37Q36142421-589BAB23-D2BC-4D47-B826-5211B63D5343Q36153645-5C6ADD3B-4BD6-4F37-A282-BAE68637D27AQ36672429-B38D34D4-04BE-467C-BFD3-2E5F092C3F1AQ37023603-06D4C7EC-3913-4FBF-B2F4-CEBE5E3800E9Q37328369-3376EAF0-6247-48CF-AF49-9370DDE57EE9Q37393632-6398B285-F99D-496D-AD27-C836EFB58200Q37503991-019BA8B5-C31D-42CB-86E1-00A5EBE18E50Q37735925-26ED301E-73D7-4D78-A980-C32C8E5E90DBQ38010028-14E9D0B7-1189-4BB8-8B1C-E761B8C5AD59Q38129820-24C94E05-871A-417D-9BF4-146462019479Q38168128-77659B6F-23B3-49F4-B7FB-EC45158E6E23Q41043244-B93ACA85-36BF-47BD-9AB5-947426C6FEA7Q41700123-8F51A35A-43C6-4D15-B6E8-BC96C41C2405Q42072625-7E8293BF-8A9A-4AA2-B5E9-7640D1F6B600Q42454443-707031D7-C436-4C8E-BA07-DD754F95ED2AQ42462455-9CE56055-AF34-48F2-BD06-4A96D01A939CQ42511613-0D782AD4-3F0D-4303-8361-791F34ED0C8BQ42520706-FE9DAFAD-AA38-4050-BBAC-D59181605F42Q46690350-7F78E08E-341B-4F18-8DA2-573F379D20F7Q59133711-C45D58E4-4472-451F-850C-A0B81CBD3C74
P2860
Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
@en
Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma.
@nl
type
label
Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
@en
Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma.
@nl
prefLabel
Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
@en
Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma.
@nl
P2093
P2860
P921
P1433
P1476
Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma
@en
P2093
Joya Emilie de Menezes Correia-Deur
Marcelo Augusto Santos
Rodrigo A Toledo
Sergio P A Toledo
P2860
P304
P356
10.1590/S1807-59322009000700015
P577
2009-01-01T00:00:00Z